[go: up one dir, main page]

BRPI0515516A - composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica - Google Patents

composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica

Info

Publication number
BRPI0515516A
BRPI0515516A BRPI0515516-9A BRPI0515516A BRPI0515516A BR PI0515516 A BRPI0515516 A BR PI0515516A BR PI0515516 A BRPI0515516 A BR PI0515516A BR PI0515516 A BRPI0515516 A BR PI0515516A
Authority
BR
Brazil
Prior art keywords
vaccine
preventing
staphylococcal
treating
immunogenic composition
Prior art date
Application number
BRPI0515516-9A
Other languages
English (en)
Inventor
Cindy Castado
Nicolas Pierre Fernand Lecrenier
Jan Poolman
Cecile Anne Neyt
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36000843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515516(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0421082A external-priority patent/GB0421082D0/en
Priority claimed from GB0421081A external-priority patent/GB0421081D0/en
Priority claimed from GB0421078A external-priority patent/GB0421078D0/en
Priority claimed from GB0421079A external-priority patent/GB0421079D0/en
Priority claimed from GB0503143A external-priority patent/GB0503143D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Priority to BR122016029840-0A priority Critical patent/BR122016029840B1/pt
Publication of BRPI0515516A publication Critical patent/BRPI0515516A/pt
Publication of BRPI0515516B1 publication Critical patent/BRPI0515516B1/pt
Publication of BRPI0515516B8 publication Critical patent/BRPI0515516B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO IMUNOGêNICA, VACINA, MéTODOS DE FABRICAR UMA VACINA E DE PREVENIR OU TRATAR INFECçãO ESTAFILOCóCICA, USO DA COMPOSIçãO IMUNOGêNICA, MéTODO DE PREPARAR UM GLOBULINA IMUNE PARA USO NA PREVENçãO OU TRATAMENTO DE INFECçãO ESTAFILOCóCICA, COMPOSIçãO FARMACêUTICA, E, USO DA COMPOSIçãO FARMCêUTICA". O presente pedido refere-se a composições imunogênicas compreendendo uma mistura de antígenos estafilocócicos que combinam antígenos tendo diferentes funções, por exemplo, combinações incluindo uma proteína estafilocócica de ligação de componente extracelular, e uma proteína transportadora estafilocócica ou uma proteína estafilocócoca de ligação de componente extracelular e um regulador estafilocócico de virulência ou toxina ou uma proteína transportadora estafilocócica e um regulador estafilocócico de virulência ou toxina. Vacinas, métodos de tratamento, usos e processos para fabricar a vacina estafilocócica são também descritos.
BRPI0515516-9A 2004-09-22 2005-09-20 Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition. BRPI0515516B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0421082A GB0421082D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421081A GB0421081D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421078.7 2004-09-22
GB0421078A GB0421078D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421079.5 2004-09-22
GB0421082.9 2004-09-22
GB0421079A GB0421079D0 (en) 2004-09-22 2004-09-22 Immunogenic composition
GB0421081.1 2004-09-22
GB0503143A GB0503143D0 (en) 2005-02-15 2005-02-15 Immunogenic composition
GB0503143.0 2005-02-15
PCT/EP2005/010184 WO2006032472A2 (en) 2004-09-22 2005-09-20 Immunogenic composition for use in vaccination against staphylococcei

Publications (3)

Publication Number Publication Date
BRPI0515516A true BRPI0515516A (pt) 2008-07-29
BRPI0515516B1 BRPI0515516B1 (pt) 2017-08-08
BRPI0515516B8 BRPI0515516B8 (pt) 2021-05-25

Family

ID=36000843

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0515516-9A BRPI0515516B1 (pt) 2004-09-22 2005-09-20 Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
BRPI0515520-7A BRPI0515520A (pt) 2004-09-22 2005-09-20 composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0515520-7A BRPI0515520A (pt) 2004-09-22 2005-09-20 composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
BR122016029840-0A BR122016029840B1 (pt) 2004-09-22 2005-09-20 Composição imunogênica, método de fabricar uma composição imunogênica, e, uso da composição imunogênica

Country Status (18)

Country Link
US (6) US20080085289A1 (pt)
EP (9) EP1791559A2 (pt)
JP (5) JP2008513409A (pt)
KR (4) KR101359930B1 (pt)
CN (2) CN102657855B (pt)
AU (3) AU2005287505A1 (pt)
BR (3) BRPI0515516B1 (pt)
CA (4) CA2584290A1 (pt)
ES (4) ES2472441T3 (pt)
HK (1) HK1155658A1 (pt)
IL (4) IL181825A0 (pt)
MA (2) MA28994B1 (pt)
MX (2) MX2007003402A (pt)
NO (2) NO20071609L (pt)
NZ (4) NZ593693A (pt)
RU (1) RU2402347C2 (pt)
WO (3) WO2006032472A2 (pt)
ZA (1) ZA200702224B (pt)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1565478T (pt) 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
US20080085289A1 (en) * 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
JP2008517918A (ja) * 2004-10-21 2008-05-29 ワイス Ｓｔａｐｈｙｌｏｃｏｃｃｕｓｅｐｉｄｅｒｍｉｄｉｓポリペプチド抗原の免疫原性組成物
JP2008517900A (ja) * 2004-10-25 2008-05-29 ザ ユニバーシティ オブ ウェスタン オンタリオ スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
PT1896061T (pt) * 2005-06-27 2019-08-01 Glaxosmithkline Biologicals Sa Composição imunogénica
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
CA2637598A1 (en) * 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US20100021503A1 (en) * 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
CN101432440B (zh) * 2006-04-24 2013-08-21 西格马食品可变资本有限公司 通过实时聚合酶链反应检测和多重、同时量化病原体的方法
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
TW200744632A (en) * 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
ATE537839T1 (de) * 2007-05-04 2012-01-15 Martin Kroenke Impfstoff zum schutz gegen staphylococcus aureus auf der basis zellwandassoziierter proteine
US8146781B2 (en) * 2007-08-09 2012-04-03 Huhtamaki, Inc. Dispenser for viscous condiments
WO2009023164A2 (en) * 2007-08-10 2009-02-19 President And Fellows Of Harvard College Induction of mucosal immunity
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
HUE027249T2 (en) 2008-03-03 2016-10-28 Novartis Ag TLR activity modulator compounds and preparations
US8241857B2 (en) * 2008-03-31 2012-08-14 Otsuka Pharmaceutical Co., Ltd. Method for detection of pneumococcus
MX2010011393A (es) * 2008-04-16 2010-11-09 Glaxosmithkline Biolog Sa Vacuna.
TWI551295B (zh) * 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
RU2532911C2 (ru) 2008-07-21 2014-11-20 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2738793A1 (en) * 2008-09-30 2010-04-08 University Of Maryland, Baltimore Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
EP2440245B1 (en) 2009-06-10 2017-12-06 GlaxoSmithKline Biologicals SA Benzonaphthyridine-containing vaccines
WO2010151544A1 (en) * 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011041003A2 (en) * 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2012122533A2 (en) * 2011-03-10 2012-09-13 The University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
BR112012004806B8 (pt) 2009-09-02 2022-10-04 Novartis Ag composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010320031B2 (en) * 2009-11-16 2015-07-16 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (Poly)-glycerolphosphate-based anti-gram positive bacterial vaccine
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
MX2012006961A (es) 2009-12-17 2012-10-03 Fina Biosolutions Llc Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas.
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
ES2743156T3 (es) 2010-04-23 2020-02-18 Serum Institute Of India Pvt Ltd Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
CN102268444B (zh) * 2010-06-03 2015-05-13 中国人民解放军军事医学科学院生物工程研究所 金黄色葡萄球菌截短SasA蛋白在大肠杆菌中的表达及应用
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012009247A1 (en) * 2010-07-15 2012-01-19 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus protein sa2412
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
WO2012085872A2 (en) * 2010-12-22 2012-06-28 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens
AU2012214677B2 (en) * 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
RU2620065C2 (ru) * 2011-02-08 2017-05-22 МЕДИММЬЮН, ЭлЭлСи Антитела, которые специфично связывают альфа-токсин staphylococcus aureus, и способы их применения
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6093760B2 (ja) 2011-06-19 2017-03-08 ニューヨーク・ユニバーシティ 抗炎症剤および殺菌剤としてのロイコトキシンｅ／ｄ
BR112013032774B1 (pt) * 2011-06-19 2020-05-05 Univ New York composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso
CA2845259A1 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
EP2844275B1 (en) 2012-04-26 2020-05-13 University of Chicago Staphylococcal coagulase antigens and methods of their use
DK2846827T3 (da) * 2012-05-09 2019-05-13 Contrafect Corp Biofilmdesintegration med plyss2-lysin
WO2013184900A2 (en) * 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme PROTECTIVE VACCINE BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2493
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
CN102898511B (zh) * 2012-10-19 2014-05-07 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌重组基因工程疫苗候选抗原i12c制备中的纯化方法
CN103087198B (zh) * 2013-01-21 2014-03-12 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原i1c及制备方法和应用
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
CN103333254A (zh) * 2013-06-21 2013-10-02 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）重组蛋白疫苗i1c的纯化方法
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
CN105483138B (zh) * 2016-01-22 2019-03-26 吉林大学 一种与致病力相关的灰霉病菌基因BcAtm1及其应用
EP3416979A4 (en) * 2016-02-12 2019-09-11 The University of Chicago COMPOSITIONS AND METHODS RELATED TO ANTIBODIES FOR NEUTRALIZING COAGULASE ACTIVITY IN STAPHYLOCOCCUS AUREUS DISEASE
WO2018074296A1 (ja) * 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
EP3752182B1 (en) 2018-02-12 2024-05-15 Inimmune Corporation Toll-like receptor ligands
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN109395072B (zh) * 2018-10-30 2021-11-30 中国兽医药品监察所 一种腐败梭菌α毒素基因工程疫苗及其生产方法
CN110055276A (zh) * 2019-01-28 2019-07-26 杨凌职业技术学院 一种金葡菌靶向抗菌肽细菌诱导型表达载体及其重组细胞
CN110892989B (zh) * 2019-06-27 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解便秘功能的副干酪乳杆菌et-22
CN112391304B (zh) * 2019-08-15 2023-04-07 上海交通大学 副血链球菌f278及其用途
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN110590910A (zh) * 2019-09-27 2019-12-20 黑龙江八一农垦大学 能够增强细胞免疫应答和抗感染作用的合成肽
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
US20230087622A1 (en) * 2020-01-29 2023-03-23 The Jackson Laboratory Bacterial admixtures
US11820989B2 (en) 2020-11-04 2023-11-21 Eligo Bioscience Phage-derived particles for in situ delivery of DNA payload into C. acnes population
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB116556A (en) 1917-06-21 1918-06-20 British Thomson Houston Co Ltd Improvements in and relating to Dynamo Electric Machines.
GB1100190A (en) * 1964-09-14 1968-01-24 Canadia Patents And Dev Ltd Somatic antigen vaccines
FR2227861B1 (pt) * 1973-05-04 1976-07-02 Anvar
JPS5452794A (en) 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0500799B1 (en) 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
CA2123811C (en) * 1991-11-22 2005-07-05 Ali Ibrahim Fattom Type i and type ii surface antigens associated with staphylococcus epidermidis
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
MX9400940A (es) 1993-02-05 1994-08-31 Smithkline Beecham Plc Peptido d1-d4 aislado de staphylococcus aureus, anticuerpos monoclonales, procedimientos para su preparacion y composiciones farmaceuticas que los incluyen.
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE231733T1 (de) 1994-01-21 2003-02-15 Powderject Vaccines Inc Gasbetätigtes element zum austragen von genmaterial
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9521146D0 (en) 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
US5700928A (en) 1995-10-16 1997-12-23 Smithkline Beecham, P.L.C. Polynucleotide encoding saliva binding protein
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
AU3399197A (en) 1996-06-18 1998-01-07 Alza Corporation Device for enhancing transdermal agent delivery or sampling
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP0957972B1 (en) 1996-12-20 2003-03-19 Alza Corporation Device and method for enhancing transdermal agent flux
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO1999027109A2 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
AU756828B2 (en) 1997-12-02 2003-01-23 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
AU761021B2 (en) 1998-07-10 2003-05-29 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
ES2308844T3 (es) * 1998-07-15 2008-12-01 The Brigham And Women's Hospital, Inc. Vacuna de polisacaridos para infecciones estafilococidas.
EP1121149A4 (en) 1998-08-31 2002-03-20 Inhibitex Inc IMMUNOTHERAPY METHOD FOR STAPHYLOCOCCAL INFECTIONS INCLUDING DONOR SELECTION AND DONOR STIMULATION
CA2341018C (en) 1998-08-31 2012-07-31 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
WO2000012131A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
EP1121135B1 (en) 1998-09-14 2009-01-28 Nabi Biopharmaceuticals Compositions of beta-glucans and specific immunoglobulins
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
WO2002045742A2 (en) * 2000-09-12 2002-06-13 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002102829A2 (en) 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
CA2453937C (en) 2001-08-02 2013-05-14 University Of Sheffield Antigenic polypeptides
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
JP2005532415A (ja) 2001-12-11 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド スタフィロコッカス・アウレウスエキソポリサッカライド及び方法
WO2003076470A1 (en) 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
PT1565478T (pt) * 2002-11-12 2017-11-14 The Brigham And Women`S Hospital Inc Vacina de polissacáridos para infeções estafilocócicas
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
NZ561879A (en) * 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20080085289A1 (en) 2004-09-22 2008-04-10 Cindy Castado Immunogenic Composition
MX2010011393A (es) * 2008-04-16 2010-11-09 Glaxosmithkline Biolog Sa Vacuna.
WO2010151544A1 (en) 2009-06-22 2010-12-29 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2012085872A2 (en) 2010-12-22 2012-06-28 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens

Also Published As

Publication number Publication date
CA2580103A1 (en) 2006-03-30
HK1155658A1 (zh) 2012-05-25
CN102657855A (zh) 2012-09-12
EP1791559A2 (en) 2007-06-06
IL182639A0 (en) 2011-08-01
KR20070058631A (ko) 2007-06-08
EP1793849A2 (en) 2007-06-13
ES2730275T3 (es) 2019-11-11
JP6594385B2 (ja) 2019-10-23
JP2015166365A (ja) 2015-09-24
NO20071609L (no) 2007-06-18
JP2008513409A (ja) 2008-05-01
US20110008385A1 (en) 2011-01-13
CA2983954C (en) 2019-09-17
NZ582441A (en) 2011-09-30
KR101508563B1 (ko) 2015-04-07
US10548963B2 (en) 2020-02-04
US20200179504A1 (en) 2020-06-11
IL223141A0 (en) 2012-12-31
JP5775005B2 (ja) 2015-09-09
EP1804833A2 (en) 2007-07-11
BRPI0515516B1 (pt) 2017-08-08
ES2540771T3 (es) 2015-07-13
KR20130087633A (ko) 2013-08-06
US20080085289A1 (en) 2008-04-10
CA2580103C (en) 2021-11-16
RU2402347C2 (ru) 2010-10-27
BRPI0515516B8 (pt) 2021-05-25
CA2983954A1 (en) 2006-03-30
AU2005287502A1 (en) 2006-03-30
WO2006032500A3 (en) 2006-06-22
ZA200702224B (en) 2016-09-28
JP2018048132A (ja) 2018-03-29
MX2007003402A (es) 2007-05-10
IL181920A (en) 2014-12-31
WO2006032500A2 (en) 2006-03-30
NO20071610L (no) 2007-06-20
NZ593693A (en) 2013-08-30
US20080095777A1 (en) 2008-04-24
RU2007110029A (ru) 2008-10-27
EP2305294A1 (en) 2011-04-06
KR20120128724A (ko) 2012-11-27
WO2006032472A2 (en) 2006-03-30
US20150328302A1 (en) 2015-11-19
EP2305296A1 (en) 2011-04-06
IL181825A0 (en) 2007-07-04
EP2305295B1 (en) 2015-04-01
EP2181714A3 (en) 2010-06-23
IL223141B (en) 2018-06-28
BRPI0515520A (pt) 2008-07-29
KR101505496B1 (ko) 2015-03-25
WO2006032475A2 (en) 2006-03-30
US20190076516A1 (en) 2019-03-14
CA2584290A1 (en) 2006-03-30
MA28995B1 (fr) 2007-11-01
AU2005287532A1 (en) 2006-03-30
EP2181714A2 (en) 2010-05-05
CA2580137A1 (en) 2006-03-30
NZ553776A (en) 2010-05-28
MX2007003400A (es) 2008-03-04
CN102657855B (zh) 2015-12-09
AU2005287502B2 (en) 2011-12-01
AU2005287505A1 (en) 2006-03-30
EP2298340A1 (en) 2011-03-23
MA28994B1 (fr) 2007-11-01
EP2893938A1 (en) 2015-07-15
JP2012107028A (ja) 2012-06-07
WO2006032472A3 (en) 2006-07-20
EP2298340B1 (en) 2014-04-16
ES2540770T3 (es) 2015-07-13
KR20070054732A (ko) 2007-05-29
EP2305294B1 (en) 2015-04-01
EP2305295A1 (en) 2011-04-06
BR122016029840B1 (pt) 2021-10-13
EP2893938B1 (en) 2019-03-06
ES2472441T3 (es) 2014-07-01
NZ553775A (en) 2010-05-28
WO2006032475A3 (en) 2007-01-25
KR101359930B1 (ko) 2014-02-12
CN101128215B (zh) 2012-10-10
CN101128215A (zh) 2008-02-20
IL181920A0 (en) 2011-07-31
AU2005287532B2 (en) 2011-09-01
JP2008513406A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
BRPI0515516A (pt) composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
RU2017123262A (ru) Иммуногенные композиции для применения в пневмококковых вакцинах
RU2508126C2 (ru) Композиции для иммунизации против staphylococcus aureus
BRPI0212999B8 (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
LU92262I2 (fr) Vaccin méningococcique groupe B (ADNr, composant, adsorbé) et ses dérivés pharmaceutiquement acceptables (BEXSERO)
DK1272213T3 (da) Mikrobielt afgivelsessystem
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
BRPI0708519B8 (pt) vesícula semelhante ao virossoma, composição farmacêutica, uso de pelo menos uma vesícula semelhante ao virossoma, e, kit para induzir uma resposta imune contra uma proteína gp41 de um vírus da imunodeficiência humana
Heininger et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
WO2006042149A3 (en) Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
MX2020008454A (es) Composicion inmunogenica que comprende antigenos estafilococicos.
WO2007145760A3 (en) Anthrax compositions and methods of use and production
BRPI0510016B8 (pt) vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2022214678A3 (en) Human metapneumo virus vaccine
WO2009077744A3 (en) Vaccines for brucellosis
BR0201889A (pt) Vacinas de ige não-anafilactogênicas
WO2002060936A3 (en) Vaccine and compositions for the prevention and treatment of neisserial infections
ATE359814T1 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
Munoz et al. Role of pertussigen (pertussis toxin) on the mouse protective activity of vaccines made from Bordetella species
BRPI0712478B8 (pt) uso de material de planta ou extrato do material de planta

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF